23 related articles for article (PubMed ID: 38736554)
1. "ACHILLES" Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in
Luo FX; Ou SI
Lung Cancer (Auckl); 2024; 15():69-73. PubMed ID: 38784059
[TBL] [Abstract][Full Text] [Related]
2. Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam.
Pham VL; Le TA; Pham CP; Hoa Nguyen TT; Do AT; Nguyen TK; Nguyen MH; Thu Hoang TA; Hao Vuong DT; Tam Nguyen DN; Khiem Dang V; Nguyen TO; Trang Vo TH; Do HK; Vu HT; Nguyen TTH; Pham VT; Trinh LH; Dung Nguyen K; Nguyen HG; Truong CM; Chau Pham TM; Nguyen TBP
Ther Adv Med Oncol; 2024; 16():17588359241242972. PubMed ID: 38736554
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.
Wang C; Zhao K; Hu S; Dong W; Gong Y; Xie C
Oncologist; 2023 Jun; 28(6):e397-e405. PubMed ID: 37116899
[TBL] [Abstract][Full Text] [Related]
4. Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.
Hsu PC; Lee SH; Chiu LC; Lee CS; Wu CE; Kuo SC; Ju JS; Huang AC; Li SH; Ko HW; Yang CT; Wang CC
Target Oncol; 2023 Mar; 18(2):195-207. PubMed ID: 36805452
[TBL] [Abstract][Full Text] [Related]
5. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam.
Vu TH; Nguyen HTT; Dao LK; Duong CK; Nguyen CV; Doan TT; Nguyen HTT; Hoang HH; Dinh DK; Le GV; Vu TT; Truong MC; Nguyen LT
Asian Pac J Cancer Prev; 2021 May; 22(5):1581-1590. PubMed ID: 34048189
[TBL] [Abstract][Full Text] [Related]
7. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
8. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
Yang JC; Schuler M; Popat S; Miura S; Heeke S; Park K; Märten A; Kim ES
J Thorac Oncol; 2020 May; 15(5):803-815. PubMed ID: 31931137
[TBL] [Abstract][Full Text] [Related]
9. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
Cho JH; Lim SH; An HJ; Kim KH; Park KU; Kang EJ; Choi YH; Ahn MS; Lee MH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Clin Oncol; 2020 Feb; 38(5):488-495. PubMed ID: 31825714
[TBL] [Abstract][Full Text] [Related]
10. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.
Ho GF; Chai CS; Alip A; Wahid MIA; Abdullah MM; Foo YC; How SH; Zaatar A; Lam KS; Leong KW; Low JS; Yusof MM; Lee EC; Toh YY; Liam CK
BMC Cancer; 2019 Sep; 19(1):896. PubMed ID: 31500587
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.
Kim Y; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
Cancer Res Treat; 2019 Apr; 51(2):502-509. PubMed ID: 29898592
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations.
Tu CY; Chen CM; Liao WC; Wu BR; Chen CY; Chen WC; Hsia TC; Cheng WC; Chen CH
Oncotarget; 2018 May; 9(36):24237-24247. PubMed ID: 29849936
[TBL] [Abstract][Full Text] [Related]
13. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
14. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
Yang JC; Sequist LV; Zhou C; Schuler M; Geater SL; Mok T; Hu CP; Yamamoto N; Feng J; O'Byrne K; Lu S; Hirsh V; Huang Y; Sebastian M; Okamoto I; Dickgreber N; Shah R; Märten A; Massey D; Wind S; Wu YL
Ann Oncol; 2016 Nov; 27(11):2103-2110. PubMed ID: 27601237
[TBL] [Abstract][Full Text] [Related]
15. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Park K; Tan EH; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; Yang JC; Lee KH; Lu S; Shi Y; Kim SW; Laskin J; Kim DW; Arvis CD; Kölbeck K; Laurie SA; Tsai CM; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L
Lancet Oncol; 2016 May; 17(5):577-89. PubMed ID: 27083334
[TBL] [Abstract][Full Text] [Related]
16. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
Yang JC; Sequist LV; Geater SL; Tsai CM; Mok TS; Schuler M; Yamamoto N; Yu CJ; Ou SH; Zhou C; Massey D; Zazulina V; Wu YL
Lancet Oncol; 2015 Jul; 16(7):830-8. PubMed ID: 26051236
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
Chiu CH; Yang CT; Shih JY; Huang MS; Su WC; Lai RS; Wang CC; Hsiao SH; Lin YC; Ho CL; Hsia TC; Wu MF; Lai CL; Lee KY; Lin CB; Yu-Wung Yeh D; Chuang CY; Chang FK; Tsai CM; Perng RP; Chih-Hsin Yang J
J Thorac Oncol; 2015 May; 10(5):793-799. PubMed ID: 25668120
[TBL] [Abstract][Full Text] [Related]
18. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
